💨 Abstract

The biotechnology industry is split between large, established companies like Amgen and Gilead, which sell treatments and generate profits, and smaller clinical-stage firms focused on drug trials. Investors in biotech face high risk and reward, with smaller firms potentially achieving high returns or face significant losses. Investing through a biotech ETF can hedge risk, offering exposure to the industry's growth.

Courtesy: WTOP Staff